비호지킨림프종 치료 시장 : 유형별, 성별 - 세계 예측(2024-2032년)

Global Non-Hodgkin Lymphoma Therapeutics Market will record a 7.4% CAGR during 2024 and 2032 due to advancements in drug development and the expansion of treatment options. Innovations in pharmaceuticals, such as targeted therapies and combination treatments, enhance the effectiveness of managing various lymphoma subtypes. These advancements address unmet medical needs and offer personalized treatment approaches. As new therapies are developed and approved, they provide more choices for patients and healthcare providers, contributing to increased market demand and a broader range of effective treatment options.

For instance, in April 2023, the FDA approved Polivy(R) (polatuzumab vedotin-piiq) combined with Rituxan(R) (rituximab) and other drugs, marking the first new B-cell lymphoma treatment in 20 years. This combo reduces disease progression risk by 27%. This new treatment offers a notable reduction in disease progression risk, enhancing therapeutic options for B-cell lymphoma patients. The introduction of such a novel therapy after 20 years underscores the market's potential for innovation and growth. It may drive increased interest and investment in the development of new therapies, influencing market dynamics and expanding treatment choices.

The non-Hodgkin lymphoma therapeutics market is classified based on type, therapy type, gender, and region.

The T-cell lymphomas segment will experience a noteworthy surge by 2032, attributed to the increasing recognition of T-cell lymphomas' complex and diverse subtypes. This segment's growth is driven by the demand for targeted therapies and advancements in understanding the specific mechanisms of T-cell lymphomas. Ongoing research and development efforts are leading to the creation of more effective and personalized treatments, addressing the unique challenges posed by T-cell lymphomas and enhancing patient outcomes, thus driving market expansion.

The chemotherapy segment will witness a substantial uptick between 2024 and 2032, propelled by its established role as a primary treatment method. Chemotherapy remains a cornerstone in managing non-Hodgkin lymphoma, effectively targeting and destroying cancer cells. Its wide range of available drugs and proven efficacy in various stages of the disease contribute to its dominant market position. As ongoing research and advancements continue to enhance chemotherapy regimens, its prevalence and importance in non-Hodgkin lymphoma treatment remain crucial.

Asia Pacific non-Hodgkin lymphoma therapeutics industry will uphold a notable CAGR through 2032, spurred by its rapidly growing healthcare infrastructure and increasing disease prevalence. The region's expanding access to advanced treatments and rising investments in oncology research contribute to this growth. In addition, improving diagnosis rates and a significant patient population further drive market expansion. Asia Pacific's advancements in healthcare and commitment to addressing cancer care needs position it as a primary contributor to the non-Hodgkin lymphoma therapeutics market forecasts.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of Non-Hodgkin lymphoma
    • 3.2.1.2 Expanding investment and R&D activities
    • 3.2.1.3 Approval of new drugs and therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 B-cell lymphomas
  • 5.2.1 Diffuse large B-cell lymphoma (DLBCL)
  • 5.2.2 Follicular lymphoma
  • 5.2.3 Mantle cell lymphoma
  • 5.2.4 Other B-cell lymphomas
• 5.3 T-cell lymphoma
  • 5.3.1 Peripheral T-cell lymphoma
  • 5.3.2 Cutaneous T-cell lymphoma
  • 5.3.3 Anaplastic large cell lymphoma
  • 5.3.4 Other T-cell lymphomas

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chemotherapy
• 6.3 Targeted therapy
• 6.4 Radiation therapy
• 6.5 Other therapy types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Astellas Pharma US, Inc.
• 9.2 AstraZeneca PLC
• 9.3 Bayer AG
• 9.4 Bristol Myers Squibb Company
• 9.5 Celgene Corporation
• 9.6 Eli Lilly and Company
• 9.7 GSK plc
• 9.8 F. Hoffmann La-Roche Ltd.
• 9.9 Janssen Pharmaceuticals Inc.
• 9.10 Seagen Inc
• 9.11 Takeda Pharmaceutical Company Ltd.
• 9.12 Teva Pharmaceutical Industries Ltd.